Artelo Biosciences Inc ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Artelo Biosciences Inc zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Artelo Biosciences Inc zu Deinem Portfolio hinzuzufügen.
SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its previously announced underwritten public offering of 441,210 shares of its ...
SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 441,210 shares of its...
SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an underwritten public offering of its common stock and/or pre-funded warran...
Patients treated with ART27.13 showed consistent improvements in weight, lean body mass, and activity While clinical benefits were observed in all treated cohorts, the best outcomes in CAReS were observed in patients titrated to the highest dose SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on ...
SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its previously announced underwritten public offering of 640,924 shares of its...
SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 640,924 shares of its...
SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an underwritten public offering of its common stock and/or pre-funded warran...
SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, affirms that, based on the strength of the positive interim results from its Phase 2 CAReS trial of ART27.13 ...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.